AstraZeneca
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell AstraZeneca and other ETFs, options, and stocks.About AZN
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company’s history roots back to the year 1913 when Astra business was formed.
AZN Key Statistics
Stock Snapshot
With a market cap of 278.62B, AstraZeneca(AZN) trades at $89.85. The stock has a price-to-earnings ratio of 30.10 and currently yields dividends of 1.7%.
On 2025-12-17, AstraZeneca(AZN) stock moved within a range of $89.85 to $91.25. With shares now at $89.85, the stock is trading 0.0% above its intraday low and -1.5% below the session's peak.
Trading volume for AstraZeneca(AZN) stock has reached 5.98M, versus its average volume of 5.9M.
The stock's 52-week range extends from a low of $61.24 to a high of $94.02.
The stock's 52-week range extends from a low of $61.24 to a high of $94.02.
AZN News
Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper...
Shares of Compugen (CGEN) added ~16% in the premarket on Wednesday after the Israel-based biotech announced an agreement with AstraZeneca (AZN) to monetize a po...
Compugen (CGEN) announced that it has agreed with AstraZeneca to monetize a portion of Compugen’s rilvegostomig future royalties. Compugen has amended the exclu...
Analyst ratings
81%
of 32 ratingsMore AZN News
The U.S. Food and Drug Administration (FDA) on Monday approved AstraZeneca Plc (NASDAQ:AZN) and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) in combination...
AstraZeneca’s (AZN) Saphnelo has been approved in the European Union, EU, for subcutaneous self-administration as a pre-filled pen for adult patients with syste...
Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper...
(RTTNews) - AstraZeneca and Daiichi Sankyo's ENHERTU (fam-trastuzumab deruxtecan-nxki), in combination with pertuzumab, has received approval in the United Stat...
AstraZeneca (AZN) and Daiichi Sankyo’s (DSNKY) ENHERTU in combination with pertuzumab has been approved in the US for the 1st-line treatment of adult patients w...
AstraZeneca (AZN) announced an update on their ongoing clinical study. Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data...
AstraZeneca (AZN) announced an update on their ongoing clinical study. Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data...